Market Overview

Shareholder Alert: Robbins Arroyo LLP Reminds Investors Apyx Medical Corporation (APYX) Sued for Misleading Shareholders

Share:

Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Apyx Medical Corporation (NASDAQ:APYX) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between August 1, 2018 and April 1, 2019. Apyx is a medical technology company that develops J-Plasma, a plasma-based surgical product for cutting, coagulation and ablation of soft tissue. It is marketed and sold as Renuvion Cosmetic Technology.

If you suffered a loss as a result of Apyx's misconduct, click here.

Apyx Medical Corporation (APYX) Accused of Misleading Investors

According to the complaint, in August 2018, Apyx announced that it had completed enrollment in its clinical study evaluating Renuvion and represented that the results would support its 510(k) submission to the FDA. Throughout December 2018 and January 2019, Apyx highlighted the submission of the 510(k) application as a milestone. The truth was revealed in February 2019 when White Diamond Research released a report alleging that Apyx's clinical study on the use of J-Plasma for dermal resurfacing may have missed its endpoints. On this news, Apyx's shares fell nearly 25% to close at $6.40 per share on February 21, 2019. On April 1, 2019, Apyx revealed it had withdrawn its 510(k) application for regulatory clearance of J-Plasma in dermal resurfacing procedures, citing concerns raised by the FDA. It also revealed that the clinical study had missed its primary efficacy endpoint. On this news, Apyx shares plummeted over 35% to close at $4.46 per share on April 2, 2019.

Apyx Medical Corporation (APYX) Shareholders Have Legal Options

Contact us to learn more:

Leo Kandinov

(800) 350-6003

lkandinov@robbinsarroyo.com

Shareholder Information Form

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com